Indicaciones del dabigatrán / Indications for dabigatran
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. impr.)
; 37(5): 252-254, mayo 2011.
Article
in Spanish
| IBECS
| ID: ibc-88085
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
El dabigatrán es un nuevo inhibidor directo de la trombina de administración oral. Este artículo revisa los resultados de los principales ensayos clínicos que justifican las indicaciones actuales en la prevención de la enfermedad tromboembólica venosa en cirugía ortopédica de cadera y rodilla, la prevención de embolia en fibrilación auricular y el tratamiento de la enfermedad tromboembólica venosa (AU)
ABSTRACT
Dabigatran is a new oral direct thrombin inhibitor. This article reviews the results of major clinical trials to justify the present indications in the prevention of venous thromboembolic disease in knee and hip orthopaedic surgery, prevention of embolism in atrial fibrillation and treatment of venous thromboembolic disease (AU)
Search on Google
Collection:
National databases
/
Spain
Health context:
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
Health problem:
Goal 9: Noncommunicable diseases and mental health
/
Target 3.4: Reduce premature mortality due to noncommunicable diseases
Database:
IBECS
Main subject:
Orthopedics
/
Atrial Fibrillation
/
Thrombin
/
Receptors, Thrombin
/
Embolism
/
Venous Thromboembolism
/
Anticoagulants
Type of study:
Etiology study
/
Risk factors
Limits:
Female
/
Humans
/
Male
Language:
Spanish
Journal:
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. impr.)
Year:
2011
Document type:
Article
Institution/Affiliation country:
Centro de Salud de Montehermoso/España
/
Hospital Ciudad de Coria/España